{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:05:46Z","timestamp":1790996746617,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40265-025-02147-3","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T20:43:18Z","timestamp":1737578598000},"page":"283-291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Current and Emerging Therapeutic Strategies for the Management of Neurotrophic Keratitis"],"prefix":"10.1007","volume":"85","author":[{"given":"Javier","family":"Lacorzana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan Ning","family":"Neo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Maubon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sibley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8336-4314","authenticated-orcid":false,"given":"Sajjad","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"2147_CR1","first-page":"1442","volume":"24","author":"RA Thoft","year":"1983","unstructured":"Thoft RA, Friend J. The X, Y, Z hypothesis of corneal epithelial maintenance. Invest Ophthalmol Vis Sci. 1983;24:1442\u20133.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2147_CR2","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0014-4835(03)00050-2","volume":"76","author":"LJ M\u00fcller","year":"2003","unstructured":"M\u00fcller LJ, Marfurt CF, Kruse F, Tervo TMT. Corneal nerves: structure, contents and function. Exp Eye Res. 2003;76:521\u201342.","journal-title":"Exp Eye Res"},{"key":"2147_CR3","unstructured":"You L, Kruse FE, V\u00f6lcker HE. Neurotrophic factors in the human cornea. Available from: www.ncbi.nlm.nih. [Accessed 10 Jan 2025]."},{"key":"2147_CR4","first-page":"1","volume":"27","author":"JD Zieske","year":"1986","unstructured":"Zieske JD, Gipson IK. Protein synthesis during corneal epithelial wound healing. Invest Ophthalmol Vis Sci. 1986;27:1\u20137.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2147_CR5","doi-asserted-by":"crossref","unstructured":"Dua HS, Said DG, Messmer EM, Rolando M, Benitez-del-Castillo JM, Hossain PN, et al. Neurotrophic keratopathy. Prog Retin Eye Res. 2018;107\u201331.","DOI":"10.1016\/j.preteyeres.2018.04.003"},{"key":"2147_CR6","doi-asserted-by":"crossref","unstructured":"Jabbour S, Ashton C, Balal S, Kaye A, Ahmad S. The management of neurotrophic keratitis. Curr Opin Ophthalmol. 2021;362\u20138.","DOI":"10.1097\/ICU.0000000000000766"},{"key":"2147_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jtos.2019.11.008","volume":"18","author":"S Saad","year":"2020","unstructured":"Saad S, Abdelmassih Y, Saad R, Guindolet D, el Khoury S, Doan S, et al. Neurotrophic keratitis: frequency, etiologies, clinical management and outcomes. Ocul Surf. 2020;18:231\u20136.","journal-title":"Ocul Surf"},{"key":"2147_CR8","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/ICO.0000000000002834","volume":"41","author":"SH Lee","year":"2022","unstructured":"Lee SH, Chun YS, Moon NJ, Kim KW. Bilateral increase of matrix metalloproteinase-9 expression in tears after the unilateral decrease of corneal sensitivity. Cornea. 2022;41:286\u201393.","journal-title":"Cornea"},{"key":"2147_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jtos.2023.09.001","volume":"30","author":"AY Cheung","year":"2023","unstructured":"Cheung AY, Holland EJ, Lee WB, Beckman KA, Tu E, Farid M, et al. Neurotrophic keratopathy: an updated understanding. Ocul Surf. 2023;30:129\u201338.","journal-title":"Ocul Surf"},{"key":"2147_CR10","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","volume":"29","author":"C Baudouin","year":"2010","unstructured":"Baudouin C, Labb\u00e9 A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312\u201334.","journal-title":"Prog Retin Eye Res"},{"key":"2147_CR11","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1167\/iovs.11-8775","volume":"53","author":"J Sarkar","year":"2012","unstructured":"Sarkar J, Chaudhary S, Namavari A, Ozturk O, Chang JH, Yco L, et al. Corneal neurotoxicity due to topical benzalkonium chloride. Invest Ophthalmol Vis Sci. 2012;53:1792\u2013802.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2147_CR12","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ajo.2008.10.019","volume":"147","author":"G Martone","year":"2009","unstructured":"Martone G, Frezzotti P, Tosi GM, Traversi C, Mittica V, Malandrini A, et al. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am J Ophthalmol. 2009;147:725-35.e1.","journal-title":"Am J Ophthalmol"},{"key":"2147_CR13","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.1167\/iovs.11-8708","volume":"53","author":"A Labb\u00e9","year":"2012","unstructured":"Labb\u00e9 A, Alalwani H, Van Went C, Brasnu E, Georgescu D, Baudouin C. The relationship between subbasal nerve morphology and corneal sensation in ocular surface disease. Invest Ophthalmol Vis Sci. 2012;53:4926\u201331.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2147_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/OPTO.S350185","volume":"15","author":"DA Semp","year":"2023","unstructured":"Semp DA, Beeson D, Sheppard AL, Dutta D, Wolffsohn JS. Artificial tears: a systematic review. Clin Optom (Auckl). 2023;15:9\u201327.","journal-title":"Clin Optom (Auckl)."},{"key":"2147_CR15","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.3390\/jcm8091478","volume":"8","author":"F Bernabei","year":"2019","unstructured":"Bernabei F, Roda M, Buzzi M, Pellegrini M, Giannaccare G, Versura P. Blood-based treatments for severe dry eye disease: the need of a consensus. J Clin Med. 2019;8:1478.","journal-title":"J Clin Med"},{"key":"2147_CR16","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.ophtha.2018.02.022","volume":"125","author":"S Bonini","year":"2018","unstructured":"Bonini S, Lambiase A, Rama P, Sinigaglia F, Allegretti M, Chao W, et al. Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis. Ophthalmology. 2018;125:1332\u201343.","journal-title":"Ophthalmology"},{"key":"2147_CR17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s41669-019-0138-z","volume":"3","author":"N Fleeman","year":"2019","unstructured":"Fleeman N, Mahon J, Nevitt S, Duarte R, Boland A, Kotas E, et al. Cenegermin for treating neurotrophic keratitis: an evidence review group perspective of a NICE Single Technology Appraisal. Pharmacoecon Open. 2019;3:453\u201361.","journal-title":"Pharmacoecon Open."},{"key":"2147_CR18","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1089\/jop.2017.0010","volume":"33","author":"M Guerra","year":"2017","unstructured":"Guerra M, Marques S, Gil JQ, Campos J, Ramos P, Rosa AM, et al. Neurotrophic keratopathy: therapeutic approach using a novel matrix regenerating agent. J Ocul Pharmacol Ther. 2017;33:662\u20139.","journal-title":"J Ocul Pharmacol Ther"},{"key":"2147_CR19","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.survophthal.2024.04.004","volume":"69","author":"GR Vera-Duarte","year":"2024","unstructured":"Vera-Duarte GR, Jimenez-Collado D, Kahuam-L\u00f3pez N, Ramirez-Miranda A, Graue-Hernandez EO, Navas A, et al. Neurotrophic keratopathy: general features and new therapies. Surv Ophthalmol. 2024;69:789\u2013804.","journal-title":"Surv Ophthalmol"},{"key":"2147_CR20","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.4103\/IJO.IJO_17_23","volume":"71","author":"R Sah","year":"2023","unstructured":"Sah R, Sharma N, Priyadarshini K, Titiyal JS. Contact lenses for the treatment of ocular surface diseases. Indian J Ophthalmol. 2023;71:1135\u201341.","journal-title":"Indian J Ophthalmol"},{"key":"2147_CR21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/ICL.0000000000000748","volume":"47","author":"E Witsberger","year":"2021","unstructured":"Witsberger E, Schornack M. Scleral lens use in neurotrophic keratopathy: a review of current concepts and practice. Eye Contact Lens. 2021;47:144\u20138.","journal-title":"Eye Contact Lens"},{"key":"2147_CR22","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/eye.2008.410","volume":"23","author":"I Rahman","year":"2009","unstructured":"Rahman I, Said DG, Maharajan VS, Dua HS. Amniotic membrane in ophthalmology: indications and limitations. Eye (Lond). 2009;23:1954\u201361.","journal-title":"Eye (Lond)"},{"key":"2147_CR23","first-page":"2623","volume":"260","author":"S Roumeau","year":"2022","unstructured":"Roumeau S, Dutheil F, Sapin V, Baker JS, Watson SL, Pereira B, et al. Efficacy of treatments for neurotrophic keratopathy: a systematic review and meta-analysis. Graefe Arch Clin Exp Ophthalmol. 2022;260:2623\u201337.","journal-title":"Graefe Arch Clin Exp Ophthalmol."},{"key":"2147_CR24","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/ICU.0000000000000578","volume":"30","author":"M Koaik","year":"2019","unstructured":"Koaik M, Baig K. Corneal neurotization. Curr Opin Ophthalmol. 2019;30:292\u20138.","journal-title":"Curr Opin Ophthalmol"},{"key":"2147_CR25","doi-asserted-by":"publisher","first-page":"E5334","DOI":"10.1097\/GOX.0000000000005334","volume":"11","author":"SC Daeschler","year":"2023","unstructured":"Daeschler SC, Woo JH, Hussein I, Ali A, Borschel GH. Corneal neurotization: preoperative patient workup and surgical decision-making. Plast Reconstr Surg Glob Open. 2023;11:E5334.","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"2147_CR26","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.3390\/jcm12062214","volume":"12","author":"DC Dragnea","year":"2023","unstructured":"Dragnea DC, Krolo I, Koppen C, Faris C, Van den Bogerd B, N\u00ed DS. Corneal neurotization: indications, surgical techniques and outcomes. J Clin Med. 2023;12:2214.","journal-title":"J Clin Med"},{"key":"2147_CR27","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2147\/OPTH.S42105","volume":"7","author":"HW Chung","year":"2013","unstructured":"Chung HW, Mehta JS. Fibrin glue for Gundersen flap surgery. Clin Ophthalmol. 2013;7:479\u201384.","journal-title":"Clin Ophthalmol"},{"key":"2147_CR28","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1097\/ICO.0000000000003145","volume":"42","author":"S Balal","year":"2023","unstructured":"Balal S, Din N, Ashton C, Ahmad S. Healing of chemical injury-related persistent corneal epithelial defects with topical insulin. Cornea. 2023;42:1000\u20134.","journal-title":"Cornea"},{"key":"2147_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/pharmaceutics16010015","volume":"16","author":"M Jaworski","year":"2023","unstructured":"Jaworski M, Lorenc A, Leszczy\u0144ski R, Mrukwa-Kominek E. Topical insulin in neurotrophic keratopathy: a review of current understanding of the mechanism of action and therapeutic approach. Pharmaceutics. 2023;16:15.","journal-title":"Pharmaceutics"},{"key":"2147_CR30","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1006\/exer.1997.0345","volume":"65","author":"M Nakamura","year":"1997","unstructured":"Nakamura M, Nishida T, Ofuji K, Reid TW, Mannis MJ, Murphy CJ. Synergistic effect of substance P with epidermal growth factor on epithelial migration in rabbit cornea. Exp Eye Res. 1997;65:321\u20139.","journal-title":"Exp Eye Res"},{"key":"2147_CR31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/ICL.0000000000000229","volume":"43","author":"K Gumus","year":"2017","unstructured":"Gumus K. Topical coenzyme Q10 eye drops as an adjuvant treatment in challenging refractory corneal ulcers: a case series and literature review. Eye Contact Lens. 2017;43:73\u201380.","journal-title":"Eye Contact Lens"},{"key":"2147_CR32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000342196","volume":"229","author":"P Fogagnolo","year":"2013","unstructured":"Fogagnolo P, Sacchi M, Ceresara G, Paderni R, Lapadula P, Orzalesi N, et al. The effects of topical coenzyme Q10 and vitamin E D-\u03b1-tocopheryl polyethylene glycol 1000 succinate after cataract surgery: a clinical and in vivo confocal study. Ophthalmologica. 2013;229:26\u201331.","journal-title":"Ophthalmologica"},{"key":"2147_CR33","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ajo.2007.03.016","volume":"144","author":"KC Yoon","year":"2007","unstructured":"Yoon KC, Heo H, Im SK, You IC, Kim YH, Park YG. Comparison of autologous serum and umbilical cord serum eye drops for dry eye syndrome. Am J Ophthalmol. 2007;144:86\u201392.","journal-title":"Am J Ophthalmol"},{"key":"2147_CR34","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.ophtha.2006.12.014","volume":"114","author":"KC Yoon","year":"2007","unstructured":"Yoon KC, You IC, Im SK, Jeong TS, Park YG, Choi J. Application of umbilical cord serum eyedrops for the treatment of neurotrophic keratitis. Ophthalmology. 2007;114:1637\u201342.","journal-title":"Ophthalmology"},{"key":"2147_CR35","first-page":"347","volume":"19","author":"D Samarkanova","year":"2021","unstructured":"Samarkanova D, Martin S, Bisbe L, Puig J, Calatayud-Pinuaga M, Rodriguez L, et al. Clinical evaluation of allogeneic eye drops from cord blood platelet lysate. Blood Transfus. 2021;19:347\u201356.","journal-title":"Blood Transfus"},{"key":"2147_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.796854","volume":"13","author":"SY Koay","year":"2022","unstructured":"Koay SY, Larkin DFP. New pharmacological approaches for the treatment of neurotrophic keratitis. Front Pharmacol. 2022;13: 796854.","journal-title":"Front Pharmacol"},{"key":"2147_CR37","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10561-021-09962-4","volume":"23","author":"ML P\u00e9rez","year":"2022","unstructured":"P\u00e9rez ML, Barreales S, Sabater-Cruz N, Martinez-Conesa EM, Vilarrodona A, Casaroli-Marano RP. Amniotic membrane extract eye drops: a new approach to severe ocular surface pathologies. Cell Tissue Bank. 2022;23:473\u201381.","journal-title":"Cell Tissue Bank"},{"key":"2147_CR38","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1007\/s10792-021-01856-4","volume":"41","author":"N Sabater-Cruz","year":"2021","unstructured":"Sabater-Cruz N, Figueras-Roca M, Ferr\u00e1n-Fuertes M, Agust\u00ed E, Mart\u00ednez-Conesa EM, P\u00e9rez-Rodr\u00edguez ML, et al. Amniotic membrane extract eye drops for ocular surface diseases: use and clinical outcome in real-world practice. Int Ophthalmol. 2021;41:2973\u20139.","journal-title":"Int Ophthalmol"},{"key":"2147_CR39","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1167\/iovs.08-2037","volume":"50","author":"SY Kim","year":"2009","unstructured":"Kim SY, Choi JS, Joo CK. Effects of nicergoline on corneal epithelial wound healing in rat eyes. Invest Ophthalmol Vis Sci. 2009;50:621\u20135.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2147_CR40","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/ICO.0000000000000348","volume":"34","author":"YC Lee","year":"2015","unstructured":"Lee YC, Kim SY. Treatment of neurotrophic keratopathy with nicergoline. Cornea. 2015;34:303\u20137.","journal-title":"Cornea"},{"key":"2147_CR41","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1080\/09273948.2021.1976214","volume":"30","author":"L Miguel-Escuder","year":"2022","unstructured":"Miguel-Escuder L, Rocha-de-Lossada C, Sabater-Cruz N, S\u00e1nchez-Gonz\u00e1lez JM, Spencer F, Mar\u00edn-Mart\u00ednez S, et al. Use of nicergoline as adjunctive treatment of neurotrophic keratitis in routine clinical practice: a case series. Ocul Immunol Inflamm. 2022;30:1926\u201330.","journal-title":"Ocul Immunol Inflamm"},{"key":"2147_CR42","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1080\/08820538.2021.1890793","volume":"36","author":"LN Kanu","year":"2021","unstructured":"Kanu LN, Ciolino JB. Nerve growth factor as an ocular therapy: applications, challenges, and future directions. Semin Ophthalmol. 2021;36:224.","journal-title":"Semin Ophthalmol."},{"key":"2147_CR43","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/j.ymthe.2017.04.020","volume":"25","author":"M Omoto","year":"2017","unstructured":"Omoto M, Suri K, Amouzegar A, Li M, Katikireddy KR, Mittal SK, et al. Hepatocyte growth factor suppresses inflammation and promotes epithelium repair in corneal injury. Mol Ther. 2017;25:1881\u20138.","journal-title":"Mol Ther"},{"key":"2147_CR44","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0006-8993(98)00610-6","volume":"803","author":"IS Zagon","year":"1998","unstructured":"Zagon IS, Sassani JW, McLaughlin PJ. Re-epithelialization of the rabbit cornea is regulated by opioid growth factor. Brain Res. 1998;803:61\u20138.","journal-title":"Brain Res"},{"key":"2147_CR45","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.brainresbull.2009.08.008","volume":"81","author":"PJ McLaughlin","year":"2010","unstructured":"McLaughlin PJ, Sassani JW, Klocek MS, Zagon IS. Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review. Brain Res Bull. 2010;81:236\u201347.","journal-title":"Brain Res Bull"},{"key":"2147_CR46","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1258\/ebm.2011.011163","volume":"236","author":"PJ McLaughlin","year":"2011","unstructured":"McLaughlin PJ, Pothering CA, Immonen JA, Zagon IS. Topical treatment with the opioid antagonist naltrexone facilitates closure of full-thickness wounds in diabetic rats. Exp Biol Med (Maywood). 2011;236:1122\u201332.","journal-title":"Exp Biol Med (Maywood)"},{"key":"2147_CR47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12886-019-1044-y","volume":"19","author":"PJ McLaughlin","year":"2019","unstructured":"McLaughlin PJ, Sassani JW, Titunick MB, Zagon IS. Efficacy and safety of a novel naltrexone treatment for dry eye in type 1 diabetes. BMC Ophthalmol. 2019;19:35.","journal-title":"BMC Ophthalmol"},{"key":"2147_CR48","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.2174\/1389450116666151019100216","volume":"17","author":"F Bignami","year":"2016","unstructured":"Bignami F, Rama P, Ferrari G. Substance P and its inhibition in ocular inflammation. Curr Drug Targets. 2016;17:1265\u201374.","journal-title":"Curr Drug Targets"},{"key":"2147_CR49","doi-asserted-by":"publisher","first-page":"78","DOI":"10.2174\/1389203724666221201093500","volume":"24","author":"Y Ying","year":"2023","unstructured":"Ying Y, Lin C, Tao N, Hoffman RD, Shi D, Chen Z, et al. Thymosin \u03b24 and actin: binding modes, biological functions and clinical applications. Curr Protein Pept Sci. 2023;24:78\u201388.","journal-title":"Curr Protein Pept Sci"},{"key":"2147_CR50","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1001\/archophthalmol.2010.53","volume":"128","author":"SP Dunn","year":"2010","unstructured":"Dunn SP, Heidemann DG, Chow CYC, Crockford D, Turjman N, Angel J, et al. Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta 4. Arch Ophthalmol. 2010;128:636\u20138.","journal-title":"Arch Ophthalmol"},{"key":"2147_CR51","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3390\/ijms24010554","volume":"24","author":"G Sosne","year":"2022","unstructured":"Sosne G, Kleinman HK, Springs C, Gross RH, Sung J, Kang S. 0.1% RGN-259 (thymosin \u03b24) ophthalmic solution promotes healing and improves comfort in neurotrophic keratopathy patients in a randomized, placebo-controlled, double-masked phase III clinical trial. Int J Mol Sci. 2022;24:554.","journal-title":"Int J Mol Sci"},{"key":"2147_CR52","first-page":"1335","volume":"62","author":"P-Y Huang","year":"2021","unstructured":"Huang P-Y, Tsao Y-P, Tou C, Lee F, Ousler G, Boehmer B, et al. Topical BRM421 Ophthalmic solution improves signs and symptoms of moderate to severe dry eye patients in clinical trials. Invest Ophthalmol Vis Sci. 2021;62:1335.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2147_CR53","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1097\/ICO.0000000000002941","volume":"41","author":"D Wirta","year":"2022","unstructured":"Wirta D, Torkildsen GL, Boehmer B, Hollander DA, Bendert E, Zeng L, et al. ONSET-1 phase 2b randomized trial to evaluate the safety and efficacy of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease. Cornea. 2022;41:1207\u201316.","journal-title":"Cornea"},{"key":"2147_CR54","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ophtha.2021.11.004","volume":"129","author":"D Wirta","year":"2022","unstructured":"Wirta D, Vollmer P, Paauw J, Chiu KH, Henry E, Striffler K, et al. Efficacy and safety of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease: the ONSET-2 phase 3 randomized trial. Ophthalmology. 2022;129:379\u201387.","journal-title":"Ophthalmology"},{"key":"2147_CR55","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1634\/theoncologist.2014-0229","volume":"20","author":"M Aapro","year":"2015","unstructured":"Aapro M, Carides A, Rapoport BL, Schmoll H-J, Zhang L, Warr D. Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. Oncologist. 2015;20:450\u20138.","journal-title":"Oncologist"},{"key":"2147_CR56","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1167\/iovs.62.3.26","volume":"62","author":"RML Vitar","year":"2021","unstructured":"Vitar RML, Barbariga M, Fonteyne P, Bignami F, Rama P, Ferrari G. Modulating ocular surface pain through neurokinin-1 receptor blockade. Invest Ophthalmol Vis Sci. 2021;62:26.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2147_CR57","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jtos.2023.09.004","volume":"30","author":"F Bonelli","year":"2023","unstructured":"Bonelli F, Demirsoy I, Lasagni Vitar RM, Fonteyne P, Ferrari G. Topical formulations of Aprepitant are safe and effective in relieving pain and inflammation, and drive neural regeneration. Ocul Surf. 2023;30:92\u2013103.","journal-title":"Ocul Surf"},{"key":"2147_CR58","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jtos.2020.09.007","volume":"19","author":"RE Ruiz-Lozano","year":"2021","unstructured":"Ruiz-Lozano RE, Hernandez-Camarena JC, Loya-Garcia D, Merayo-Lloves J, Rodriguez-Garcia A. The molecular basis of neurotrophic keratopathy: diagnostic and therapeutic implications. A review. Ocul Surf. 2021;19:224\u201340.","journal-title":"Ocul Surf"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02147-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02147-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02147-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T09:33:56Z","timestamp":1741599236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02147-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2147"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02147-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"7 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Javier Lacorzana, Yan Ning Neo, Laura Maubon, Daniel Sibley and Sajjad Ahmad have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"JL contributed to the development, writing and editing of the manuscript; YNN contributed to the writing of the manuscript; LM contributed to the writing of the manuscript; DS contributed to the writing and editing of the manuscript; SA contributed to the development, writing and editing of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}